- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05345600
MILTA vs Placebo Use Comparison for the Management of Pain Related to Perineal Scars Following Delivery (MILTADoIP)
A Pilot Randomized Trial Comparing the Use of MILTA vs Placebo for the Management of Pain Related to Perineal Scars Following Delivery
The incidence of perineal scars after a pregnancy is high, either related to an episiotomy or to spontaneous perineal tears. These perineal scars can result in acute pain but also in chronic pain for some women. Medical treatment includes level 1 and 2 analgesics and, even for a few women, level 3 analgesic.
The MILTA® uses photons which are emitted with low intensity in the visible and near infrared combining 5 physical principles to reduce pain : 1- The NPCL (Nano-Pulsed Cold Laser) emissions in coherent infrared light, at 905 nanometers; 2- Non-coherent emissions, pulsed by trichromatic RGB CSM diodes (400 to 650 nm); 3- Continuous non-coherent infrared emission monochromatic diodes at 905 nm; 4- A constant circular magnetic field (200 millitesla) equivalent to the terrestrial magnetic field and 5- The effect of magnetic tunnel which potentiates the light propagation. MILTA® treatment has been shown to be effective in various managements of pain, but has never been used in pain related to perineal scars.
This randomized controlled trial aims at assessing MILTA vs placebo to reduce pain related to perineal scars after pregnancy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Marie-Chantal BLANCHARD
- Phone Number: 03 22 08 74 24
- Email: blanchard.marie-chantal@chu-amiens.fr
Study Locations
-
-
Picardie
-
Amiens, Picardie, France, 80054
- Recruiting
- CHU Amiens Picardie
-
Contact:
- Marie-Chantal BLANCHARD
- Phone Number: 03 22 08 74 24
- Email: blanchard.marie-chantal@chu-amiens.fr
-
Sub-Investigator:
- Sandrine SORIOT-THOMAS, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- vaginal delivery less than 24h before inclusion
- perineal scar with pain assessed as > 3/10 with a numerical scale
- 18-years-old or older
- registration to the French medical system
- speaking and writing French
- written informed consent signed
Exclusion Criteria:
- woman under 18-years-old
- woman under law liberty restriction
- women unable to understand the written informed consent
- no written informed consent signed
- previous perineal surgery
- delivery with a caesarian section
- vaginal delivery with no perineal scar
- vaginal delivery with infected perineal scar
- women with restrictions for the use of level 1 analgesic
- women requiring level 2 or 3 analgesics for other reasons
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo
|
Each woman will be included within the 6h after delivery (to ensure at least 2 days with the treatment / placebo).
Once the written informed consent is obtained, the patient will be randomized in one of the 2 groups ("MILTA" or "Placebo"): 2 sessions are planned (the first one between 6h and 24h after delivery and the second one day after the first session).
The woman will be lying on an exam bed.
After a skin cleansing, the MILTA probe covered with a specific single use protection will be placed facing the scar.
A 10-min session will include 5 min with the "analgesia mode" on followed with 5 min with the "healing mode" on in the MILTA group.
For the placebo group, the procedure will be identical, with the probe switched OFF.
To ensure that the red light is observable in the bedroom in both groups, a second probe will be used, facing the ceiling of the exam bedroom (and not the woman) for the 10 minutes of the procedure.
|
Experimental: MILTA
The MILTA® uses photons which are emitted with low intensity in the visible and near infrared combining 5 physical principles to reduce pain
|
Each woman will be included within the 6h after delivery (to ensure at least 2 days with the treatment / placebo).
Once the written informed consent is obtained, the patient will be randomized in one of the 2 groups ("MILTA" or "Placebo"): 2 sessions are planned (the first one between 6h and 24h after delivery and the second one day after the first session).
The woman will be lying on an exam bed.
After a skin cleansing, the MILTA probe covered with a specific single use protection will be placed facing the scar.
A 10-min session will include 5 min with the "analgesia mode" on followed with 5 min with the "healing mode" on in the MILTA group.
For the placebo group, the procedure will be identical, with the probe switched OFF.
To ensure that the red light is observable in the bedroom in both groups, a second probe will be used, facing the ceiling of the exam bedroom (and not the woman) for the 10 minutes of the procedure.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pain level
Time Frame: day 3
|
Pain Level will be determined with EQ-5D instrument. The EQ-5D index scores were derived from the current UK tariff, which has a maximum value of 1 and a minimum value of -0.59. EQ-5D comprises a short descriptive system questionnaire and a visual analogue scale (EQ VAS) that are cognitively undemanding. |
day 3
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI2021_843_0049
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
Clinical Trials on MILTA probe
-
ElsanCompleted
-
University of FloridaFlorida Probe CorporationCompletedPeriodontitis | Diagnoses DiseaseUnited States
-
Sheffield Teaching Hospitals NHS Foundation TrustCompletedPeriodontal DiseaseUnited Kingdom
-
Pelvital USA, Inc.Completed
-
Mayo ClinicCompletedVascular Access ComplicationUnited States
-
Children's Hospital of PhiladelphiaWithdrawnLaryngopharyngeal RefluxUnited States
-
University of Wisconsin, MadisonRecruitingOxygen ConsumptionUnited States
-
University of AberdeenNHS Grampian; Softcell Medical LtdNot yet recruitingAcute Compartment SyndromeUnited Kingdom
-
Massachusetts General HospitalCompleted
-
Hospital Universitari Vall d'Hebron Research InstituteCompleted